cyltezo
boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - leki immunosupresyjne - proszę zapoznać się z rozdziałem 4. 1 charakterystyki produktu leczniczego w dokumencie informacyjnym o produkcie.
methylphenidate mylan 27 mg tabletki o przedłużonym uwalnianiu
mylan s.a.s. - methylphenidati hydrochloridum - tabletki o przedłużonym uwalnianiu - 27 mg
zidenac 1 mg/ml krople doustne, roztwór
zentiva, k.s. - dimetindeni maleas - krople doustne, roztwór - 1 mg/ml
nonafact
sanquin plasma products b.v. - ludzki czynnik krzepnięcia ix - hemofilia b - antykrościeryczne - leczenie i profilaktyka krwawień u pacjentów z hemofilią b (wrodzony niedobór czynnika ix).
unidox solutab 100 mg tabletki do sporządzania zawiesiny doustnej
cheplapharm arzneimittel gmbh - doxycyclinum - tabletki do sporządzania zawiesiny doustnej - 100 mg
bendamustine actavis 2,5 mg/ml proszek do sporządzania koncentratu roztworu do infuzji
actavis group ptc ehf. - bendamustini hydrochloridum - proszek do sporządzania koncentratu roztworu do infuzji - 2,5 mg/ml
aciclovir accord 25 mg/ml koncentrat do sporządzania roztworu do infuzji
accord healthcare polska sp. z o.o. - aciclovirum - koncentrat do sporządzania roztworu do infuzji - 25 mg/ml
jayempi
nova laboratories ireland limited - azathioprine - odrzucenie wniosku - leki immunosupresyjne - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
okitask 25 mg tabletki musujące
dompe farmaceutici s.p.a. - ketoprofenum lysinum - tabletki musujące - 25 mg
belem 0,8 mg
dyrekcja generalna lasów państwowych bitwy warszawskiej 1920, 02-362 warszawa - cypermetryna - 8 g - insektycyd